MAGEA3 and cancer: This epitope was also previously reported by another MAGE-A3 related cancer vaccine study 33 In addition, the proportion of MAGE-A3-Mp1 and MAGE-A3-Mp2 epitope-specific CD8+ T cells increased by 237% and 199% after stimulation, respectively (Figure 2D-E), which is consistent with the previous study concluding Mp1 and Mp2 were immunogenic epitopes 32.